286 related articles for article (PubMed ID: 30944026)
1. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
3. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
[TBL] [Abstract][Full Text] [Related]
5. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
[TBL] [Abstract][Full Text] [Related]
6. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
7. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
[TBL] [Abstract][Full Text] [Related]
8. Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
Ozaki Y; Muto S; Takagi H; Watanabe M; Inoue T; Fukuhara M; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Ohsugi J; Hoshino M; Shio Y; Tanaka D; Nanamiya H; Imai JI; Isogai T; Watanabe S; Suzuki H
Cancer Immunol Immunother; 2020 Jan; 69(1):127-134. PubMed ID: 31807880
[TBL] [Abstract][Full Text] [Related]
9. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Sturgill EG; Misch A; Jones CC; Luckett D; Fu X; Schlauch D; Jones SF; Burris HA; Spigel DR; McKenzie AJ
Oncologist; 2022 Mar; 27(3):175-182. PubMed ID: 35274716
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S; Li W; Wu S; Stewart R; Morsli N; Raja R; Zhang Q; Ye J; He P; Shetty J; Yovine A; Holoweckyj N; Real K; Walker J; Wrona M; de Los Reyes M; Barker C; Whiteley J; Haddad R; Licitra L; Ferris R; Fayette J; Zandberg DP; Siu LL; Mesía R
Clin Cancer Res; 2023 Jun; 29(11):2066-2074. PubMed ID: 36806911
[TBL] [Abstract][Full Text] [Related]
11. Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB.
Fridland S; Choi J; Nam M; Schellenberg SJ; Kim E; Lee G; Yoon N; Chae YK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462324
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
[TBL] [Abstract][Full Text] [Related]
14. New methodology of TMB assessment from tissue and liquid biopsy in NSCLC.
Křížová Ľ; Šafaříková M; Kalousová M; Pfeiferová L; Kuběna AA; Vočka M; Ulrych J; Franková V; Petruželka L; Zima T; Feltl D
PLoS One; 2022; 17(9):e0275121. PubMed ID: 36155654
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
16. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
[TBL] [Abstract][Full Text] [Related]
17. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.
Fan Y; Liu Y; Wang L; Cai Y; Cao W; Sun W; Zou X; Li B; Zhang Z; Cai S; Chuai S; Han Y; Pan X; Huang D
EBioMedicine; 2023 May; 91():104564. PubMed ID: 37094467
[TBL] [Abstract][Full Text] [Related]
18. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
[TBL] [Abstract][Full Text] [Related]
19. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
[TBL] [Abstract][Full Text] [Related]
20. Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Ma Y; Li Q; Du Y; Cai J; Chen W; Zhao G; Liu X; Li H; Ma L; Huang Y; Zhou Y
Front Oncol; 2021; 11():640761. PubMed ID: 34055609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
